Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much controversy about the implementation of this PrEP regimen in other countrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Jean-Michel, Pintado, Claire, Gatey, Caroline, Ponscarme, Diane, Charbonneau, Pierre, Loze, Benedicte, Rozenbaum, Willy, Delaugerre, Constance
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751938/
https://www.ncbi.nlm.nih.gov/pubmed/23972284
http://dx.doi.org/10.1186/1741-7015-11-186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751938/
https://www.ncbi.nlm.nih.gov/pubmed/23972284
http://dx.doi.org/10.1186/1741-7015-11-186

Ejemplares similares